8:00 am Chair’s Opening Remarks

Approaching Neuroinflammation as a Therapeutic Target for Neurodegenerative Diseases

8:15 am The Interface of Inflammation & Cell Death: Disease Progression in Multiple Sclerosis & Beyond

8:45 am Microglia: Suppress or Promote?

9:15 am Assessment of Antibody Profiling in Neurodegenerative Disease

9:45 am Speed Networking

10:30 am Morning Refreshments

Identifying Translational Biomarkers to Effectively Translate into the Clinic

11:30 am From Animal to Man: Building Target Engagement to Proof of Concept Pathway

  • Johan Luthman Executive Vice President, Research & Development, Lundbeck

12:00 pm Stabbing in the Dark: Biomarkers of Microglial Pathway Activation

12:30 pm The Challenge of Developing Translatable Biomarkers to Guide the Clinical Interrogation of LRRK2 Kinase Inhibitors for Parkinson’s Disease

  • Matthew Fell Principal Scientist, Neuroimmunology, Merck Research Laboratories

1:00 pm Lunch & Networking

Utilizing Technology Advances to Better Understand the Neuroimmune System

2:00 pm Single Cell Sequencing & Spatial Transcriptomic Approaches to Characterize Human Cells & Tissues

  • Rebecca Mathew Senior Scientist, GpGx-Genome Sciences, Merck Research Laboratories

2:30 pm Moving Away from Microglial Targets & Appreciating Astrocyte Contribution

3:00 pm Exploring Nuclear Imaging Approaches to Understand & Monitor Neuroinflammation


• TSPO imaging and its limitations
• Current efforts to image alternative aspects of neuroinflammation including
P2X7R, CSF1R, COX2 and ROS.
• Pre-targeting Imaging and utilization of large molecules to monitor

3:00 pm Afternoon Refreshments & Networking

Connecting Neuroinflammation to Human Patients

4:00 pm The Role of Microglial BIN1 in Alzheimer’s Disease: From Genetics to Target Validation

4:30 pm Panel Discussion: Are We Chasing the Wrong Phenomenon?

  • Malu Tansey Director, Center for Translational Research in Neurodegenerative Disease & the Parkinson’s Foundation Research Center, The University of Florida College of Medicine
  • Richard Ransohoff Venture Partner, Third Rock Ventures

5:00 pm Chair’s Closing Remarks

5:15 pm Scientific Poster Session